{
    "nctId": "NCT01803828",
    "officialTitle": "Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A",
    "inclusionCriteria": "* age 45-80 years;\n* Diagnosis of Type 2 Diabetes from at least 3 years;\n* HbA1c \\< 10%;\n* normal blood pressure or controlled hypertension;\n* BMI \\< 40;\n* SIV \u2265 11 mm men, \u2265 10 women and/or diastolic dysfunction (PW-doppler and TDI)\n* Must have minimum age of 45 Years\n* Must have maximum age of 80 Years",
    "exclusionCriteria": "* current use of PDE5 inhibitors;\n* congenital or valvular cardiomyopathy;\n* ischemic heart disease;\n* proliferative retinopathy;\n* contraindications to tadalafil use (hypersensitivity to tadalafil, nitrates use, severe cardiovascular disorders such as unstable angina or severe heart failure, severe hepatic impairment, blood pressure \\<90/50 mmHg, recent history of stroke or myocardial infarction and known hereditary degenerative retinal disorders such as retinitis pigmentosa);\n* contraindications to CMR imaging with mdc (patients with implant such as cardiac pacemakers, insulin pumps, neurostimulators and cochlear implants, or metallic fragments, clips or devices, or severe renal failure with GFR \\< 30mL/min/1.73 m2);\n* cronic or acute atrial fibrillation."
}